UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 61,102 Shares of Illumina, Inc. $ILMN

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC reduced its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 3.9% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,502,137 shares of the life sciences company’s stock after selling 61,102 shares during the quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Illumina were worth $264,121,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. BlackRock Inc. acquired a new stake in shares of Illumina in the 2nd quarter valued at approximately $3,374,423,000. Primecap Management Co. CA bought a new position in Illumina during the 2nd quarter worth approximately $617,981,000. Jupiter Topco LLC acquired a new position in Illumina during the second quarter valued at approximately $358,652,000. WCM Investment Management LLC grew its holdings in Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after purchasing an additional 1,851,848 shares during the period. Finally, Bank of New York Mellon Corp bought a new stake in Illumina in the second quarter valued at approximately $293,846,000. 89.42% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the stock. Royal Bank Of Canada increased their target price on shares of Illumina from $170.00 to $230.00 and gave the stock an “outperform” rating in a report on Friday, July 31st. Deutsche Bank Aktiengesellschaft lowered shares of Illumina to a “hold” rating in a report on Wednesday, August 5th. TD Cowen upped their price objective on shares of Illumina from $192.00 to $210.00 and gave the company a “hold” rating in a research report on Friday, July 31st. Stifel Nicolaus raised their price objective on Illumina from $155.00 to $225.00 and gave the stock a “buy” rating in a research note on Friday, July 31st. Finally, Evercore reissued an “outperform” rating on shares of Illumina in a research note on Monday, July 6th. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, six have given a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $188.40.

Illumina Stock Performance

Shares of ILMN opened at $213.63 on Tuesday. The firm has a market cap of $32.26 billion, a P/E ratio of 39.86, a PEG ratio of 3.03 and a beta of 1.44. Illumina, Inc. has a twelve month low of $88.00 and a twelve month high of $231.81. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. The firm’s 50 day moving average price is $195.10 and its two-hundred day moving average price is $156.54.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm’s quarterly revenue was up 9.4% on a year-over-year basis. During the same period last year, the business posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, analysts forecast that Illumina, Inc. will post 5.36 EPS for the current fiscal year.

Insiders Place Their Bets

In other Illumina news, SVP Patricia Leckman sold 783 shares of Illumina stock in a transaction dated Friday, June 5th. The stock was sold at an average price of $162.59, for a total value of $127,307.97. Following the sale, the senior vice president owned 21,259 shares of the company’s stock, valued at $3,456,500.81. This trade represents a 3.55% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Christensen Jakob Wedel sold 1,033 shares of the business’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total value of $197,840.16. Following the completion of the sale, the senior vice president owned 14,023 shares in the company, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 1,799,688 shares of company stock worth $379,517,231. Corporate insiders own 2.90% of the company’s stock.

Illumina Company Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.